Brenus Pharma is a thriving French private biotech company dedicated to tackling the pressing challenge of cancer recurrence. Recognizing that 90% of solid tumours face relapse due to current limitations, Brenus is at the forefront of reshaping the oncology landscape with its innovative platform centred around cutting-edge cancer vaccines. The company’s Stimulated Tumor Cells (STC) technology platform is a game-changer, empowering the immune system to anticipate mechanisms leading to tumour cell relapse. This approach presents a revolutionary method to prevent cancer recurrence, addressing a critical medical need.